Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
m |
||
Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*3/10/2021: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' | *3/10/2021: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' | ||
− | + | ==History of changes in EMA indication== | |
+ | *8/24/2017: Initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' AV-951 | *'''Code name:''' AV-951 | ||
Line 26: | Line 27: | ||
[[Category:Renal cell carcinoma medications]] | [[Category:Renal cell carcinoma medications]] | ||
− | [[Category:EMA approved | + | [[Category:EMA approved in 2017]] |
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] |
Revision as of 14:48, 1 January 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established (work in progress)
Patient drug information
History of changes in FDA indication
- 3/10/2021: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
History of changes in EMA indication
- 8/24/2017: Initial authorization
Also known as
- Code name: AV-951
- Brand name: Fotivda